BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 15529060)

  • 21. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
    Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
    [No Abstract]   [Full Text] [Related]  

  • 22. Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure.
    Adams KF
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S4-13. PubMed ID: 15160833
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The role of aldosterone-antagonists in the treatment of congestive heart failure].
    Fügedi K
    Orv Hetil; 2005 Apr; 146(14):645-8. PubMed ID: 15889538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aldosterone antagonists: a new treatment option for patients with post-myocardial infarction heart failure.
    Ajani AE; Marwick TH; Krum H
    Cardiovasc Revasc Med; 2006; 7(4):234-6. PubMed ID: 17174870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New treasures from old? EPHESUS. Eplerenome Post-AHI Heart Failure Efficacy and Survival Study.
    Pfeffer MA
    Cardiovasc Drugs Ther; 2001 Jan; 15(1):11-3. PubMed ID: 11504157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blocking aldosterone in heart failure.
    Shafiq MM; Miller AB
    Ther Adv Cardiovasc Dis; 2009 Oct; 3(5):379-85. PubMed ID: 19661156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Aldosterone receptor blockade after acute myocardial infarction with heart failure].
    Bauersachs J; Ertl G
    Med Klin (Munich); 2006 Jun; 101(6):458-66. PubMed ID: 16767569
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J; Gerber RA; Roberts C; Gheorghiade M
    Am J Ther; 2010; 17(5):446-54. PubMed ID: 20844344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eplerenone: selective aldosterone antagonism in management of cardiovascular and renal disease.
    Brennan BJ; Martin NE
    J Am Pharm Assoc (2003); 2004; 44(5):604-10; quiz 610-1. PubMed ID: 15496047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The clinical pharmacology of eplerenone.
    Muldowney JA; Schoenhard JA; Benge CD
    Expert Opin Drug Metab Toxicol; 2009 Apr; 5(4):425-32. PubMed ID: 19379127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction.
    Fraccarollo D; Galuppo P; Hildemann S; Christ M; Ertl G; Bauersachs J
    J Am Coll Cardiol; 2003 Nov; 42(9):1666-73. PubMed ID: 14607457
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The EMPHASIS-HF study].
    Boccanelli A; Agostoni P
    G Ital Cardiol (Rome); 2011 May; 12(5):315-8. PubMed ID: 21593949
    [No Abstract]   [Full Text] [Related]  

  • 36. Eplerenone: a selective aldosterone receptor antagonist (SARA).
    Delyani JA; Rocha R; Cook CS; Tobert DS; Levin S; Roniker B; Workman DL; Sing YL; Whelihan B
    Cardiovasc Drug Rev; 2001; 19(3):185-200. PubMed ID: 11607037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone antagonists in heart failure.
    Guglin M; Kristof-Kuteyeva O; Novotorova I; Pratap P
    J Cardiovasc Pharmacol Ther; 2011 Jun; 16(2):150-9. PubMed ID: 21160084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aldosterone-receptor antagonists in heart failure: insights after EMPHASIS-HF.
    Jacob MS; Tang WH
    Curr Heart Fail Rep; 2011 Mar; 8(1):7-13. PubMed ID: 21207206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.